RWE: Source Of The Problem in China

Prostate cancer

% of physicians who changed treatment due to COVID-19

Type of Change Made
- Observation/Active Surveillance vs active therapy
  - China: 4%
- Recommend hospice vs. active therapy
  - China: 11%
- Use of surgery
  - China: 4%
- Use of radiotherapy
  - China: 25%
- Use of neoadjuvant systemic therapy
  - China: 21%
- Use of adjuvant systemic therapy
  - China: 18%
- Enrollment in clinical trials for active therapy
  - China: 18%
- Use of PD-1 / PD-L1 inhibitors
  - China: 21%
- Use of all-oral regimens
  - China: 18%
- Use of "drug holidays" or treatment-free intervals
  - China: 18%
- Biomarker testing instead of not testing patients
  - China: 21%

N=28

Values <5% are not labelled. Response is % of change among physicians. Values rounded to the nearest whole number.

KANTAR
RWE: The Source Of The Problem in the US 2020

88305 SURGICAL PATHOLOGY TEST VOLUMES

MONTH COUNT (1 = JAN18)

January  June
Focus Needs To Shift Onto What’s Next

The cancer chain reaction

Unknown chain reaction demand for CDx biomarker testing?

- 750,000 COVID-19 tests per day

20-30% drop in diagnosis and CDx biomarker testing

Pre-COVID Cancer Testing Bandwidth in the Market

COVID-19 test demand on the lab infrastructure


Potentially 5-fold increase in demand for COVID-19 testing

CAPACITY GAP & LAB OVERSTRETCH HAS POTENTIAL TO DELAY DIAGNOSIS, TESTING AND ULTIMATELY TREATMENT ACCESS

Diaceutics